Article Per Year (5 Year)
p-Index From 2019 - 2024
0
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer Jurnal Penyakit Dalam Indonesia
Djumhana Atmakusuma, Djumhana
Unknown Affiliation
Health Professions Medicine & Pharmacology

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Indonesian Journal of Cancer

 1 
Efficacy and Safety of In-Asia-Manufactured rhG-CSF 300 mcg As Primary Prophylaxis for Prevention of CHOP Chemotherapy-induced Severe Neutropenia in Elderly Patients with Lymphoma Non-Hodgkin Reksodiputro, Harryanto; Djoerban, Zubairi; Tambunan, Karmel L.; Sudoyo, Aru W.; Widjanarko, Abidin; Atmakusuma, Djumhana; Syafei, Syafrizal; Prayogo, Nugroho; Hukom, Ronald; Ranuhardy, Dody; Jack, Zakifman; Harsal, Asrul; -, Noorwati S; Karsono, Bambang; Effendi, Shufrie; Tadjoedin, Hilman
Indonesian Journal of Cancer Vol 3, No 1 (2009): Jan - Mar 2009
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (790.74 KB)

Abstract

Penelitian open-label, non-komparatif ini dilakukan untuk mengevaluasi efektivitas dan keamanan recombinant human G-CSF produksi Asia sebagai profilaksis primer dalam pencegahan neutropenia derajat berat pada pasien usia lanjut (>60 tahun) dengan limfoma non-Hodgkin (LNH) derajat sedang dan lanjut (stadium II,III,IV) yang mendapat terapi CHOP (siklofosfamid, doksorubisin, vinkristin). Profilaksis primer recombinant human G-CSF (rhG-CSF) produksi Asia dapat mengurangi median durasi neutropenia derajat 4 pada siklus sitostatistika ke-1 dan ke-2 menjadi tiga hari, sementara median durasi neutropenia derajat 3 pada siklus sitostistika ke-1 menjadi dua hari dan pada siklus sitostatistika ke-2 menjadi dua setengah hari, dari median durasi neutropenia grade 4 dan grade 3 tanpa G-CSF, yaitu empat dan lima hari berurutan. Febrile neutropenia ditemukan pada 7 pasien yang mendapat rhG-CSF produksi Asia (24.1%), lebih rendah jika dibandingkan studi tanpa rhG-CFS (31.3-34% FN). Tiga pasien mendapat rhG-CSF produksi Asia (10,3%) dirawat inap akibat febrile neutropenia, lebih rendah jika dibandingkan rawat inap pada studi tanpa rhG-CSF (24-28%). Kejadian yang tidak diinginkan terbanyak adalah mual dan muntah yang terjadi pada 9 (31%) pasien. Sebagai kesimpulan, penggunaan rhG-CSF produksi Asia untuk profilaksis primer pada pasien LNH usia lanjut yang mendapat regimen CHOP dapat mengurangi durasi neutropenia, mengurangi kejadian febrile neutropenia, dan angka rawat inap akibat febrile neutropenia.Kata kunci : Efektivitas, keamanan, G-CSF, LNH pada usia lanjut
Guidelines in Chemotherapy Atmakusuma, Djumhana; Hospital, Dharmais Cancer
Indonesian Journal of Cancer Vol 2, No 5 (2008): Workshop 2008
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Guidelines in Chemotherapy full text: http://www.scribd.com/doc/45151303/Guidelines-in-Chemotherapy
Evaluation of Kidney Injury Molecule-1 (KIM-1) and Neutrophil Gelatinase-Associated Lipocalin (NGAL) Urinary Levels for Detecting Kidney Dysfunction in Patients With Nasopharyngeal Cancer Treated With Cisplatin-Based Treatment Rejeki, Marliana Sri; Arozal, Wawaimuli; Setiabudy, Rianto; Atmakusuma, Djumhana
Indonesian Journal of Cancer Vol 12, No 2 (2018): April-June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (951.677 KB) | DOI: 10.33371/ijoc.v12i2.581

Abstract

Background: Cisplatin has a potency of causing nephrotoxicity. Serum BUN and creatinine levels have been well-known for detecting kidney dysfunction; while KIM-1 and NGAL urine levels are relatively new measurements. The study was aimed to evaluate urinary KIM-1 and NGAL level to detect kidney dysfunction in patients with advanced stage NPC who received cisplatin-based chemotherapy.Methods: The study was a cohort-prospective study with 3 subject groups, i.e. patients who had never received and who had received 75-100 mg/m2 cisplatin-based chemotherapy as well as those who had never received 40 mg/m2 cisplatin-based chemotherapy. The levels of urinary KIM-1, NGAL and serum level of BUN and creatinine were measured before and after receiving cisplatin. Statistical analyses were ANOVA, Pearson, Spearman, Kolmogorov-Smirnov test and SPSS version 22.0.Result: There was a significant difference of delta BUN level (p=0.0001) and delta urinary NGAL level (p = 0.025) before and after treatment in all three groups; while delta KIM-1 level showed no significant difference in all three groups (p=0.275). Cisplatin may cause accumulated nephrotoxicity, which has dose-dependent manner.Conclusion: Measuring urinary NGAL level can detect an early stage of kidney dysfunction; however, it still cannot replace the role of BUN. Measurement of urinary KIM-1 level cannot detect kidney dysfunction.
Co-Authors Abidin Widjanarko Aru W. Sudoyo Asrul Harsal, Asrul Bambang Karsono Dadang Makmun Dedy G Sudrajat, Dedy G Dharmais Cancer Hospital, Dharmais Cancer Dody Ranuhardy, Dody Harryanto Reksodiputro, Harryanto HILMAN TADJOEDIN, HILMAN Idrus Alwi Karmel L. Tambunan Kuntjoro Harimurti Noorwati S -, Noorwati S Nugroho Prayogo Rejeki, Marliana Sri Rianto Setiabudy Ronald Hukom S, Ivan Onggo Shufrie Effendi, Shufrie Siti Setiati Sudrajat, Dedy G. Syafrizal Syafei, Syafrizal Wawaimuli Arozal Wulyo Rajabto Zakifman Jack, Zakifman Zubairi Djoerban